JP2019514872A - （非）アルコ−ル性脂肪肝炎又は非アルコ−ル性脂肪性肝疾患の治療のためのナルメフェン（ＮＡＬＭＥＦＥＮＥ）、ナルトレキソン（ｎａｌｔｒｅｘｏｎｅ）及びその関連誘導体の応用 - Google Patents

（非）アルコ−ル性脂肪肝炎又は非アルコ−ル性脂肪性肝疾患の治療のためのナルメフェン（ＮＡＬＭＥＦＥＮＥ）、ナルトレキソン（ｎａｌｔｒｅｘｏｎｅ）及びその関連誘導体の応用 Download PDF

Info

Publication number
JP2019514872A
JP2019514872A JP2018554716A JP2018554716A JP2019514872A JP 2019514872 A JP2019514872 A JP 2019514872A JP 2018554716 A JP2018554716 A JP 2018554716A JP 2018554716 A JP2018554716 A JP 2018554716A JP 2019514872 A JP2019514872 A JP 2019514872A
Authority
JP
Japan
Prior art keywords
compound
nash
preventing
group
nafld
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018554716A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019514872A5 (enExample
Inventor
エドウィン エスシー ウー
エドウィン エスシー ウー
ピーター ジェイエス チウ
ピーター ジェイエス チウ
メイ メイ−チー スー
メイ メイ−チー スー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TaiwanJ Pharmaceuticals Co Ltd
Original Assignee
TaiwanJ Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TaiwanJ Pharmaceuticals Co Ltd filed Critical TaiwanJ Pharmaceuticals Co Ltd
Publication of JP2019514872A publication Critical patent/JP2019514872A/ja
Publication of JP2019514872A5 publication Critical patent/JP2019514872A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018554716A 2016-04-22 2017-04-20 （非）アルコ−ル性脂肪肝炎又は非アルコ−ル性脂肪性肝疾患の治療のためのナルメフェン（ＮＡＬＭＥＦＥＮＥ）、ナルトレキソン（ｎａｌｔｒｅｘｏｎｅ）及びその関連誘導体の応用 Pending JP2019514872A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662326435P 2016-04-22 2016-04-22
US62/326,435 2016-04-22
US201662395436P 2016-09-16 2016-09-16
US62/395,436 2016-09-16
PCT/US2017/028529 WO2017184819A1 (en) 2016-04-22 2017-04-20 Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease

Publications (2)

Publication Number Publication Date
JP2019514872A true JP2019514872A (ja) 2019-06-06
JP2019514872A5 JP2019514872A5 (enExample) 2020-03-05

Family

ID=58668969

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018554716A Pending JP2019514872A (ja) 2016-04-22 2017-04-20 （非）アルコ−ル性脂肪肝炎又は非アルコ−ル性脂肪性肝疾患の治療のためのナルメフェン（ＮＡＬＭＥＦＥＮＥ）、ナルトレキソン（ｎａｌｔｒｅｘｏｎｅ）及びその関連誘導体の応用

Country Status (10)

Country Link
US (1) US10045977B2 (enExample)
EP (1) EP3445363A1 (enExample)
JP (1) JP2019514872A (enExample)
KR (1) KR20180129909A (enExample)
CN (2) CN109069503A (enExample)
AU (1) AU2017253228B2 (enExample)
BR (1) BR112018071705A2 (enExample)
CA (1) CA3021788C (enExample)
RU (1) RU2717677C1 (enExample)
WO (1) WO2017184819A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
EP3712254A1 (en) 2014-05-28 2020-09-23 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
CA2963704A1 (en) 2014-10-17 2016-04-21 Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
EP4177335A1 (en) 2016-05-05 2023-05-10 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
US20190247373A1 (en) * 2016-07-14 2019-08-15 Children's Hospital Medical Center Methods for treating fibrosis
SG11201903697WA (en) 2016-11-04 2019-05-30 Childrens Hospital Med Ct Liver organoid compositions and methods of making and using same
EP3548507A4 (en) 2016-12-05 2020-07-15 Children's Hospital Medical Center COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF
EP3609997A4 (en) 2017-04-14 2021-03-03 Children's Hospital Medical Center COMPOSITIONS OF STEM CELLS FROM MULTIPLE DONOR CELLS AND THEIR PREPARATION PROCEDURES
US12297457B2 (en) 2017-10-10 2025-05-13 Children's Hospital Medical Center Esophageal tissue and/or organoid compositions and methods of making same
EP3727394A4 (en) 2017-12-21 2021-09-08 Children's Hospital Medical Center DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF
US12421500B2 (en) 2018-07-26 2025-09-23 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
JP2021535753A (ja) 2018-09-12 2021-12-23 チルドレンズ ホスピタル メディカル センター 造血幹細胞およびその派生体の生成のためのオルガノイド組成物
WO2020160371A1 (en) 2019-02-01 2020-08-06 The University Of Hong Kong Innervated organoid compositions and methods of making same
CA3141814A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
CN114174494A (zh) 2019-05-31 2022-03-11 儿童医院医学中心 产生和扩增造血干细胞的方法
CA3236690A1 (en) 2021-11-18 2023-05-25 Ju Hee Kim Sustained-release injectable composition containing naltrexone and method for preparing same
CN118234488A (zh) 2021-11-18 2024-06-21 创技公司株式会社 包含难溶性药物的微粒的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102048733A (zh) * 2010-12-23 2011-05-11 武汉同源药业有限公司 盐酸纳美芬的医药用途
US20150335638A1 (en) * 2009-07-16 2015-11-26 Mallinckrodt Llc (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
AU2003234621A1 (en) 2002-05-17 2003-12-02 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US7923454B2 (en) * 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
TR201002473A2 (tr) * 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
MY180160A (en) * 2013-04-22 2020-11-23 Cadila Healthcare Ltd A novel composition for nonalcoholic fatty liver disease (nafld)
EP3416619A2 (en) * 2016-02-18 2018-12-26 Immune Therapeutics, Inc. Method for inducing a sustained immune response

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150335638A1 (en) * 2009-07-16 2015-11-26 Mallinckrodt Llc (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
CN102048733A (zh) * 2010-12-23 2011-05-11 武汉同源药业有限公司 盐酸纳美芬的医药用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ACTA PHYSIOL. HUNG., vol. 101, no. 3, JPN6019030502, 2014, pages 341 - 352, ISSN: 0004388759 *

Also Published As

Publication number Publication date
BR112018071705A2 (pt) 2019-02-19
AU2017253228B2 (en) 2020-04-09
CN117137917A (zh) 2023-12-01
US20170304294A1 (en) 2017-10-26
RU2717677C1 (ru) 2020-03-25
CA3021788A1 (en) 2017-10-26
EP3445363A1 (en) 2019-02-27
AU2017253228A1 (en) 2018-09-27
AU2017253228A8 (en) 2019-01-17
KR20180129909A (ko) 2018-12-05
US10045977B2 (en) 2018-08-14
CA3021788C (en) 2021-08-03
WO2017184819A1 (en) 2017-10-26
CN109069503A (zh) 2018-12-21

Similar Documents

Publication Publication Date Title
AU2017253228B2 (en) Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease
JP2019514872A5 (enExample)
AU2011230081A1 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
WO2021143912A1 (zh) 无细胞脂肪提取液对脂肪肝及其并发症的治疗作用
WO2016195355A1 (ko) 필버톤의 신규한 용도
WO2024106716A1 (ko) 2'-푸코실락토오스를 포함하는 치매 개선 또는 치료용 조성물
TWI828155B (zh) 吡咯并嘧啶類化合物的用途
KR20150130352A (ko) 지방간 질환을 치료하는 방법
EP2608783A1 (en) Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis
CN113813281A (zh) 肌苷在制备预防和治疗结核病药物中的应用
CN114555577A (zh) 用于治疗门静脉炎症和纤维化的噻吩衍生物
CN110731962B (zh) 小檗碱、黄连碱或其活性代谢产物、及其盐在预防和/或治疗尿酸性肾病药物中的应用
JP6914256B2 (ja) 膵臓脂肪浸潤を予防または治療し、膵臓脂肪浸潤に起因する膵臓病変、糖尿病または他の関連症状を緩和するための組成物、および方法
US20180318290A1 (en) Use of nalmefene in non-alcoholic steatohepatitis
TW201813646A (zh) 納美芬(nalmefene)在非酒精性脂肪肝炎(nash)的應用
CN103690535A (zh) 盐酸去亚甲基小檗碱在制备预防和/或治疗肝纤维化药物中的应用
CN110731964B (zh) 化合物as1842856的用途
CN113368107B (zh) 包含小檗碱和苦参碱的药物组合物及其治疗或预防非酒精性脂肪性肝病的用途
WO2018030650A1 (ko) 국화잎 추출물을 유효성분으로 포함하는 항비만 조성물
WO2019242764A1 (zh) 糖苷类化合物在制备防治糖尿病并发症的药物中的应用
JP6702184B2 (ja) 低アルブミン血症の改善剤
US20210008015A1 (en) Hepatoprotectent phenylbutyratyrate drug conjugates, and their compositions preparation and methods of use thereof
KR20190130241A (ko) 크로몰린 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물
CN117700427A (zh) 一种daca及其制备方法、应用和药物组合物
KR20260033973A (ko) 오에노테인 b를 포함하는 대사이상 간 질환의 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190813

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191107

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20200110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200722

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201124